DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016" report to their offering. Dravet ...
Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's ...
DUBLIN--(BUSINESS WIRE)--The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering.
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy SAN DIEGO, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Jim Brennan and McKelvey Homes ...
(MENAFN- GlobeNewsWire - Nasdaq) Company Coverage includes Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical, Biocodex, Longboard Pharmaceuticals, Stoke Therapeutics, Thermo Fisher Scientific, Harmony ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback